As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
7 Analysts have issued a Ensysce Biosciences Inc forecast:
7 Analysts have issued a Ensysce Biosciences Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 7.41 7.41 |
415%
415%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -6.65 -6.65 |
31%
31%
|
|
| Net Profit | -6.58 -6.58 |
42%
42%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.
| Head office | United States |
| CEO | D. Kirkpatrick |
| Employees | 8 |
| Founded | 2003 |
| Website | ensysce.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


